Extended Data Fig. 1: Lymphocytes populations in ChAdOx1 nCoV-19 and GEMCOVAC-OM cohorts.
From: An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
(A) Total T-cells (CD3+ cells) population in % of lymphocyte gate applied, (B) total CD4+ T-cells population in % of total CD3+ T-cells, (C) total CD8+ T-cells in % of total CD3+ T-cells in ChAdOx1 nCoV-19 (n = 35) and GEMCOVAC-OM (n = 71) cohorts. (D) Total CD19+ CD20+ B-cells in % of CD3− gated population in ChAdOx1 nCoV-19 (n = 34) and GEMCOVAC-OM (n = 67) cohorts. Box plots represent the median, 25th and 75th percentiles. Whiskers extend from the minimum to maximum values in the data set. Change in T-cells from baseline to day 29 and day 90 was assessed using a two-sided paired t-test or Wilcoxon sign ranked test based on normality. Expression at day 29 and day 90 in both the groups was compared using a two-sided t-test or Wilcoxon rank sum test based on normality.
